Experts clarify conflicting criteria for diagnosing polycystic ovary syndrome
The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of polycystic ovary syndrome, the most common hormone disorder in women of reproductive age and a leading cause of infertility.
The CPG, entitled “Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline” will appear in the December 2013 issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of The Endocrine Society.
Polycystic ovary syndrome, or PCOS, affects about 5 million women in the United States, according to the National Institutes of Health. The condition causes diverse symptoms, and its causes are poorly understood. The definition and even the name of PCOS have been subject to debate. An NIH panel concluded in January 2013 that the name’s focus on a specific symptom – ovarian cysts - that is not present in all PCOS cases caused confusion about the condition. Three separate diagnostic classification systems have been developed to help identify PCOS.
“The Endocrine Society’s CPG is designed to help physicians and patients navigate our evolving understanding of this complex condition,” said Richard S. Legro, MD, of the Penn State University College of Medicine, and chair of the task force that authored the guideline. “The Society’s recommendations allow physicians to make the diagnosis if clear symptoms are present without resorting to universal hormone tests or ultrasound screening.”
In the CPG, The Endocrine Society recommends that a diagnosis be made if adult women have two of the three cardinal features of PCOS (diagnostic criteria supported by the NIH panel):
Excess production of male hormones called androgens.
Anovulation, a condition where the ovary does not release a mature egg each month. This causes irregular menstrual cycles.
The formation of clusters of pearl-size cysts containing immature eggs in the ovaries, which is called polycystic ovaries.
Other recommendations from the CPG include:
Because women with PCOS face an increased risk of pregnancy complications such as gestational diabetes, preterm delivery and preeclampsia that can be exacerbated by obesity, women should have their body mass index, blood pressure and oral glucose tolerance assessed prior to conceiving;
Following diagnosis, women with PCOS should be examined for skin and hair complications including excess hair growth and acne;
Although women with PCOS have some of the same risk factors associated with the development of endometrial cancer, they should not routinely undergo ultrasound screening for endometrial thickness;
To gauge metabolic risk, adolescents and adult women with PCOS should be screened for increased obesity using body mass index and waist circumference measurements;
Clinicians should give adolescents and adult women with PCOS an oral glucose tolerance test to check for type 2 diabetes or impaired glucose tolerance because they are at increased risk of these conditions; and
Initial treatment of type 2 diabetes or impaired glucose tolerance in women with PCOS should be diet and exercise, with metformin as a second-line therapy.
The Hormone Health Network, The Endocrine Society’s public education arm, has published a fact sheet that explains how PCOS affects the body and outlines treatment options at http://www.hormone.org/diseases-and-conditions/womens-health/polycystic-ovary-syndrome.
Other members of The Endocrine Society task force that developed this CPG include: Silva A. Arslanian of Children’s Hospital of Pittsburgh; David A. Ehrmann of University of Chicago; Kathleen M. Hoeger of University of Rochester Medical Center in Rochester, NY; M. Hassan Murad of The Mayo Clinic in Rochester, MN; Renato Pasquali of Orsola-Malpighi Hospital in Bologna, Italy; and Corrine K. Welt of Massachusetts General Hospital in Boston, MA.
The Society established the CPG Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis and treatment of endocrine-related conditions. Each CPG is created by a task force of topic-related experts in the field. Task forces rely on scientific reviews of the literature in the development of CPG recommendations. The Endocrine Society does not solicit or accept corporate support for its CPGs. All CPGs are supported entirely by Society funds.
Founded in 1916, The Endocrine Society is the world’s oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society’s membership consists of over 16,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland.
Jenni Glenn Gingery
The Endocrine Society